A retrospective survey was performed to establish @entity1 and graft outcome for all 41 @entity1 at our centre receiving @entity3446 (SRL) in combination with calcineurin inhibition (CNI) as primary therapy for the 6 years prior to March 2002. @entity1 mortality [12%; n = 5 (TTP, @entity706 , @entity2583 , and small bowel perforation] was significantly higher at 3 months compared with those not receiving SRL, but not thereafter. 12.8% had delayed graft function and 33% had one or more episodes of rejection in the first 6 months. Mean GFR at 12 months was significantly lower (47.3 mL/min) in the SRL group compared with those not receiving SRL (51.3 mL/min). Twenty-two @entity1 had a 12-month protocol biopsy; CNI @entity137 was present in 36%. SRL was associated with significant hyperlipidaemia (serum @entity165 , 5.2 +/- 1.4 at baseline vs 7.3 +/- 1.7 mmol/L at 3 months, P <.001; @entity1674 , 2.3 +/- 1.4 at baseline vs 2.7 +/- 1.1 mmol/L at 3 months, P <.05). Mild @entity882 occurred in 23% but was not associated with @entity548 events. LDH increased by 62%, remaining elevated out to 2 years post engraftment. Seven @entity1 developed insulin requiring @entity6 , similar to the rate observed in our general transplant population.Thus, in this early experience, SRL in combination with CNI was associated with significant mortality and morbidity including CNI @entity137 , presumably a reflection of a heavy burden of immunosuppression. However, 1-year graft survival on SRL was similar to the mean Australia-wide graft survival regardless of immunosuppression. The future use of SRL may center around CNI sparing and avoidance type protocols.

XXXX : a single center experience in combination with calcineurin inhibitors.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity2583 :: ('MESH:D009091', 'Disease') :: ['mucormycosis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhagic'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity3446 :: (MESH:D020123,Chemical) :: ['Sirolimus']
